Participant Flow Report for NCT03421379 - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Composition: Participant Flow Report for NCT03421379

version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en

Profile: ParticipantFlowReport

url: https://fevir.net/resources/Composition/399871

identifier: FEvIR Object Identifier/399871, FEvIR Linking Identifier/NCT03421379-participant-flow-report

status: Final

type: Participant Flow Report

date: 2025-12-11 20:35:21+0000

author: [No author listed.]

title: Participant Flow Report for NCT03421379

custodian: Computable Publishing LLC

RelatesTos

Type

Target[x]

Cite As

Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json.

Generated Narrative: Group #FG000

Profile: ExposureGroup
name: NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride
description:
A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.

type: Person
membership: Enumerated
Characteristics
- Code Value[x] Exclude
* Research Study from which this is a flow group NCT03421379 false

Generated Narrative: Group #FG001

Profile: ExposureGroup
name: NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder
description:
A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.

type: Person
membership: Enumerated
Characteristics
- Code Value[x] Exclude
* Research Study from which this is a flow group NCT03421379 false

Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-1-group-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: STARTED at Period 1
Statistics
- StatisticType Quantity
* Count 34

Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-1-group-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: STARTED at Period 1
Statistics
- StatisticType Quantity
* Count 41

Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-1-group-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-1-group-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: Received at Least One Dose of Study Drug at Period 1
Statistics
- StatisticType Quantity
* Count 33

Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-1-group-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-1-group-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: Received at Least One Dose of Study Drug at Period 1
Statistics
- StatisticType Quantity
* Count 39

Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-1-group-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-1-group-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: COMPLETED at Period 1
Statistics
- StatisticType Quantity
* Count 32

Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-1-group-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-1-group-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: COMPLETED at Period 1
Statistics
- StatisticType Quantity
* Count 37

Generated Narrative: Evidence #NCT03421379-flow-milestone-3-Period-1-group-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-3-Period-1-group-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: NOT COMPLETED at Period 1
Statistics
- StatisticType Quantity
* Count 2

Generated Narrative: Evidence #NCT03421379-flow-milestone-3-Period-1-group-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-3-Period-1-group-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: NOT COMPLETED at Period 1
Statistics
- StatisticType Quantity
* Count 4

Generated Narrative: Evidence #NCT03421379-flow-reason-Period-1-group-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-reason-Period-1-group-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: Reasons for withdraw at Period 1
statistic
statisticType: Count
category: Withdrawal by Subject
quantity: 0
statistic
statisticType: Count
category: Physician Decision
quantity: 1
statistic
statisticType: Count
category: Did not receive treatment
quantity: 1

Generated Narrative: Evidence #NCT03421379-flow-reason-Period-1-group-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-reason-Period-1-group-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: Reasons for withdraw at Period 1
statistic
statisticType: Count
category: Withdrawal by Subject
quantity: 1
statistic
statisticType: Count
category: Physician Decision
quantity: 1
statistic
statisticType: Count
category: Did not receive treatment
quantity: 2

Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: STARTED at Washout Period (3 to 14 Days)
Statistics
- StatisticType Quantity
* Count 32

Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: STARTED at Washout Period (3 to 14 Days)
Statistics
- StatisticType Quantity
* Count 37

Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: COMPLETED at Washout Period (3 to 14 Days)
Statistics
- StatisticType Quantity
* Count 32

Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: COMPLETED at Washout Period (3 to 14 Days)
Statistics
- StatisticType Quantity
* Count 37

Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: NOT COMPLETED at Washout Period (3 to 14 Days)
Statistics
- StatisticType Quantity
* Count 0

Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: NOT COMPLETED at Washout Period (3 to 14 Days)
Statistics
- StatisticType Quantity
* Count 0

Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-2-group-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-2-group-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: STARTED at Period 2
Statistics
- StatisticType Quantity
* Count 32

Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-2-group-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-2-group-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: STARTED at Period 2
Statistics
- StatisticType Quantity
* Count 37

Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-2-group-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-2-group-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: COMPLETED at Period 2
Statistics
- StatisticType Quantity
* Count 32

Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-2-group-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-2-group-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: COMPLETED at Period 2
Statistics
- StatisticType Quantity
* Count 37

Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-2-group-FG000

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-2-group-FG000
title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Nasal Powder/Glucagon Hydrochloride
variableDefinition
variableRole: Outcome
observed: NOT COMPLETED at Period 2
Statistics
- StatisticType Quantity
* Count 0

Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-2-group-FG001

Profile: ParticipantFlowEvidence
identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-2-group-FG001
title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
UseContexts
- Code Value[x]
* Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence
variableDefinition
variableRole: Population
observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variableDefinition
variableRole: Outcome
observed: NOT COMPLETED at Period 2
Statistics
- StatisticType Quantity
* Count 0